1. Pink Sheet
  2. >>Compliance
  3. >>Distribution/Supply Chain

Medicare Incentives For Quality Drugs Should Not Wait For US FDA Ratings, Experts Tell Congress

 
• By Bowman Cox

Medicare payment for higher quality drugs would help abate shortages, experts with the Brookings Institution, Civica Rx and University of California say. Brookings’ Wosińska explains how hospitals could identify quality generic injectable drug manufacturers without waiting for FDA quality ratings.

Thumbs up for drug quality
why pay for quality • Source: Shutterstock

 Medicare could help prevent shortages in generic injectable drugs by rewarding hospitals for procuring high-quality products from reliable manufacturers, and such incentives could proceed without waiting for the US Food and Drug Administration to rate manufacturer reliability, experts told the Senate Finance Committee during a 5 December hearing on drug shortage solutions.

The Finance panel is viewing shortages from a reimbursement perspective because its legislative jurisdiction includes programs such as Medicare; it does not

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

More from Compliance